Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Akili, Inc.AKLI · Entity 89130 | Former Director and 10% Owner | August 19, 2022 | August 23, 2022 |
| Benitec Biopharma Inc.BNTC · Entity 5596 | Director | December 01, 2025 | December 03, 2025 |
| Biohaven Ltd.BHVN · Entity 4379 | Director | April 28, 2026 | May 01, 2026 |
| Biohaven Pharmaceutical Holding Co Ltd.BHVN · Entity 123269 | Director | October 03, 2022 | October 03, 2022 |
| Social Capital Suvretta Holdings Corp. IIDNAB · Entity 125597 | Director · President · 10% owner | August 16, 2021 | August 16, 2021 |
| Social Capital Suvretta Holdings Corp. IVDNAD · Entity 123913 | Director · President · 10% owner | August 16, 2021 | August 16, 2021 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Akili, Inc.
Report date August 19, 2022 · Filed August 23, 2022
Jointly reported with SCS Sponsor I LLC, Cowen Aaron, ChaChaCha DNA I, LLC
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 6,860,000 |
Reported balance
After 2022-08-19 transaction · row 1
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 1 · 2022-08-19 · Exercise / conversion · Acquired 6,220,000 · Balance 6,860,000 F1: The Class B ordinary shares, par value $0.0001 per share (each a "Class B ordinary share"), held by the reporting owner, SCS Sponsor I LLC (the "Sponsor"), converted to the Issuer's common stock, par value $0.0001 per share ("Common Stock"), on a one-for-one basis upon the consummation of the business combination between the Issuer and Akili Interactive Labs, Inc. (the "Business Combination"). F2: The Sponsor is managed by its managers, Chamath Palihapitiya and Kishan Mehta. A majority of the voting interests of the Sponsor are held by SC SPAC Holdings LLC, the successor by merger to ChaChaCha DNA I, LLC ("SC SPAC Holdings"). Messrs. Mehta and Cowen may be deemed to control the other member of the Sponsor. Messrs. Mehta and Cowen and SC SPAC Holdings may be deemed to beneficially own shares held by the Sponsor by virtue of their direct or indirect interests in the Sponsor or their shared control over the Sponsor, as the case may be. |
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2022-08-19 transaction · row 2
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 2 · 2022-08-19 · Other · Disposed 6,860,000 · Balance 0 F3: Represents the distribution for no consideration by the Sponsor of 6,860,000 shares of Common Stock to its members pro rata in accordance with their respective interests. |
| Class B ordinary sharesSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2022-08-19 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2022-08-19 · Exercise / conversion · Disposed 6,220,000 · Balance 0 F4: The Class B ordinary shares converted to Common Stock on a one-for-one basis upon the consummation of the Business Combination. F1: The Class B ordinary shares, par value $0.0001 per share (each a "Class B ordinary share"), held by the reporting owner, SCS Sponsor I LLC (the "Sponsor"), converted to the Issuer's common stock, par value $0.0001 per share ("Common Stock"), on a one-for-one basis upon the consummation of the business combination between the Issuer and Akili Interactive Labs, Inc. (the "Business Combination"). F2: The Sponsor is managed by its managers, Chamath Palihapitiya and Kishan Mehta. A majority of the voting interests of the Sponsor are held by SC SPAC Holdings LLC, the successor by merger to ChaChaCha DNA I, LLC ("SC SPAC Holdings"). Messrs. Mehta and Cowen may be deemed to control the other member of the Sponsor. Messrs. Mehta and Cowen and SC SPAC Holdings may be deemed to beneficially own shares held by the Sponsor by virtue of their direct or indirect interests in the Sponsor or their shared control over the Sponsor, as the case may be. |
Filing footnotes · ownership attribution and instrument terms
F1: The Class B ordinary shares, par value $0.0001 per share (each a "Class B ordinary share"), held by the reporting owner, SCS Sponsor I LLC (the "Sponsor"), converted to the Issuer's common stock, par value $0.0001 per share ("Common Stock"), on a one-for-one basis upon the consummation of the business combination between the Issuer and Akili Interactive Labs, Inc. (the "Business Combination").
F2: The Sponsor is managed by its managers, Chamath Palihapitiya and Kishan Mehta. A majority of the voting interests of the Sponsor are held by SC SPAC Holdings LLC, the successor by merger to ChaChaCha DNA I, LLC ("SC SPAC Holdings"). Messrs. Mehta and Cowen may be deemed to control the other member of the Sponsor. Messrs. Mehta and Cowen and SC SPAC Holdings may be deemed to beneficially own shares held by the Sponsor by virtue of their direct or indirect interests in the Sponsor or their shared control over the Sponsor, as the case may be.
F3: Represents the distribution for no consideration by the Sponsor of 6,860,000 shares of Common Stock to its members pro rata in accordance with their respective interests.
F4: The Class B ordinary shares converted to Common Stock on a one-for-one basis upon the consummation of the Business Combination.
Benitec Biopharma Inc.
Report date December 01, 2025 · Filed December 03, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Options (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $12.23 · Expires 2035-12-01 | Direct | 35,000 |
Reported balance
After 2025-12-01 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2025-12-01 · Grant · Acquired 35,000 · Balance 35,000 F1: Consists of options to purchase shares of the Issuer's common stock awarded to Mr. Mehta in connection with his role as a member of the Issuer's Board of Directors. Mr. Mehta, as Portfolio Manager for Averill Master Fund, Ltd. and Averill Madison Master Fund, Ltd (the "Funds") is holding such options for the benefit of the Funds, and as such Mr. Mehta disclaims beneficial ownership of such options. The Funds, and Suvretta Capital Management, LLC ("Suvretta Capital"), the investment manager of the Funds, may be deemed to have an indirect pecuniary interest in such options because Suvretta Capital has rights to receive the benefit of director compensation provided in respect of Mr. Mehta's board service. F2: The stock options will vest on the earlier of the Issuer's next annual stockholders' meeting or December 1, 2026. |
Filing footnotes · ownership attribution and instrument terms
F1: Consists of options to purchase shares of the Issuer's common stock awarded to Mr. Mehta in connection with his role as a member of the Issuer's Board of Directors. Mr. Mehta, as Portfolio Manager for Averill Master Fund, Ltd. and Averill Madison Master Fund, Ltd (the "Funds") is holding such options for the benefit of the Funds, and as such Mr. Mehta disclaims beneficial ownership of such options. The Funds, and Suvretta Capital Management, LLC ("Suvretta Capital"), the investment manager of the Funds, may be deemed to have an indirect pecuniary interest in such options because Suvretta Capital has rights to receive the benefit of director compensation provided in respect of Mr. Mehta's board service.
F2: The stock options will vest on the earlier of the Issuer's next annual stockholders' meeting or December 1, 2026.
Biohaven Ltd.
Report date April 28, 2026 · Filed May 01, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Options (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $9.61 · Expires 2036-04-28 | Direct | 68,693 |
Reported balance
After 2026-04-28 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-04-28 · Grant · Acquired 68,693 · Balance 68,693 F1: The shares subject to this stock option will vest in full on the earlier of (a) April 28, 2027 or (b) the date of the 2027 Annual Meeting of Shareholders, in each case subject to the Reporting Person's continuous service with the Issuer through such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares subject to this stock option will vest in full on the earlier of (a) April 28, 2027 or (b) the date of the 2027 Annual Meeting of Shareholders, in each case subject to the Reporting Person's continuous service with the Issuer through such vesting date.
Biohaven Pharmaceutical Holding Co Ltd.
Report date October 03, 2022 · Filed October 03, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common SharesSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2022-10-03 transaction · row 1
1 source rowRow 1 · 2022-10-03 · Disposition to issuer · Disposed 10,640 · Balance 0 F1: Under the Agreement and Plan of Merger, dated as of May 9, 2022 (the "Merger Agreement"), by and among the Issuer, Pfizer Inc. ("Pfizer") and a wholly owned subsidiary of Pfizer ("Merger Sub"), following satisfaction or waiver of the closing conditions set forth in the Merger Agreement, on October 3, 2022 Merger Sub merged with and into the Issuer with the Issuer surviving as the surviving company (the "Merger"). F2: In the Merger, each common share of the Issuer (each, a "Common Share") outstanding immediately prior to the effective time of the Merger (other than certain excluded shares pursuant to the terms of the Merger Agreement), was converted into the right to receive the merger consideration in cash of $148.50, without interest, less any withholding taxes (the "Merger Consideration"). |
| Restricted Share Unit AwardSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2022-10-03 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2022-10-03 · Disposition to issuer · Disposed 1,875 · Balance 0 F3: In connection with the distribution ("Distribution") by the Issuer to holders of its common shares of all the outstanding common shares of Biohaven Ltd. ("SpinCo"), each outstanding restricted share unit of the Issuer was adjusted such that such restricted share unit became a restricted share unit in respect of common shares of SpinCo and a restricted share unit in respect of Common Shares (each such restricted share unit, a "Post-Spin Issuer RSU"). At the effective time of the Merger, each outstanding Post-Spin Issuer RSU was automatically cancelled in exchange for the right to receive (without interest) an amount in cash equal to the product of (i) the number of Common Shares subject to such Post-Spin Issuer RSU, with any performance conditions applicable to such Post-Spin Issuer RSU deemed achieved at 100%, and (ii) the Merger Consideration, less any withholding taxes. |
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $95.33 · Expires 2032-04-28 | Direct | 0 |
Reported balance
After 2022-10-03 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2022-10-03 · Disposition to issuer · Disposed 8,239 · Balance 0 F4: In connection with the Distribution, each outstanding option to purchase common shares of the Issuer was adjusted such that such option became an option to acquire SpinCo common shares and an option to acquire Common Shares (each such option, a "Post-Spin Issuer Option"). At the effective time of the Merger, each outstanding Post-Spin Issuer Option was automatically cancelled in exchange for the right to receive (without interest) an amount in cash equal to the product of (i) the excess, if any, of the Merger Consideration over the exercise price per Common Share of such Post-Spin Issuer Option and (ii) the number of Common Shares subject to such Post-Spin Issuer Option, less any withholding taxes. |
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $90.91 · Expires 2031-06-15 | Direct | 0 |
Reported balance
After 2022-10-03 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2022-10-03 · Disposition to issuer · Disposed 13,004 · Balance 0 F4: In connection with the Distribution, each outstanding option to purchase common shares of the Issuer was adjusted such that such option became an option to acquire SpinCo common shares and an option to acquire Common Shares (each such option, a "Post-Spin Issuer Option"). At the effective time of the Merger, each outstanding Post-Spin Issuer Option was automatically cancelled in exchange for the right to receive (without interest) an amount in cash equal to the product of (i) the excess, if any, of the Merger Consideration over the exercise price per Common Share of such Post-Spin Issuer Option and (ii) the number of Common Shares subject to such Post-Spin Issuer Option, less any withholding taxes. |
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $50.85 · Expires 2029-12-18 | Direct | 0 |
Reported balance
After 2022-10-03 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2022-10-03 · Disposition to issuer · Disposed 15,000 · Balance 0 F4: In connection with the Distribution, each outstanding option to purchase common shares of the Issuer was adjusted such that such option became an option to acquire SpinCo common shares and an option to acquire Common Shares (each such option, a "Post-Spin Issuer Option"). At the effective time of the Merger, each outstanding Post-Spin Issuer Option was automatically cancelled in exchange for the right to receive (without interest) an amount in cash equal to the product of (i) the excess, if any, of the Merger Consideration over the exercise price per Common Share of such Post-Spin Issuer Option and (ii) the number of Common Shares subject to such Post-Spin Issuer Option, less any withholding taxes. |
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $36.64 · Expires 2029-01-17 | Direct | 0 |
Reported balance
After 2022-10-03 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2022-10-03 · Disposition to issuer · Disposed 20,000 · Balance 0 F4: In connection with the Distribution, each outstanding option to purchase common shares of the Issuer was adjusted such that such option became an option to acquire SpinCo common shares and an option to acquire Common Shares (each such option, a "Post-Spin Issuer Option"). At the effective time of the Merger, each outstanding Post-Spin Issuer Option was automatically cancelled in exchange for the right to receive (without interest) an amount in cash equal to the product of (i) the excess, if any, of the Merger Consideration over the exercise price per Common Share of such Post-Spin Issuer Option and (ii) the number of Common Shares subject to such Post-Spin Issuer Option, less any withholding taxes. |
Filing footnotes · ownership attribution and instrument terms
F1: Under the Agreement and Plan of Merger, dated as of May 9, 2022 (the "Merger Agreement"), by and among the Issuer, Pfizer Inc. ("Pfizer") and a wholly owned subsidiary of Pfizer ("Merger Sub"), following satisfaction or waiver of the closing conditions set forth in the Merger Agreement, on October 3, 2022 Merger Sub merged with and into the Issuer with the Issuer surviving as the surviving company (the "Merger").
F2: In the Merger, each common share of the Issuer (each, a "Common Share") outstanding immediately prior to the effective time of the Merger (other than certain excluded shares pursuant to the terms of the Merger Agreement), was converted into the right to receive the merger consideration in cash of $148.50, without interest, less any withholding taxes (the "Merger Consideration").
F3: In connection with the distribution ("Distribution") by the Issuer to holders of its common shares of all the outstanding common shares of Biohaven Ltd. ("SpinCo"), each outstanding restricted share unit of the Issuer was adjusted such that such restricted share unit became a restricted share unit in respect of common shares of SpinCo and a restricted share unit in respect of Common Shares (each such restricted share unit, a "Post-Spin Issuer RSU"). At the effective time of the Merger, each outstanding Post-Spin Issuer RSU was automatically cancelled in exchange for the right to receive (without interest) an amount in cash equal to the product of (i) the number of Common Shares subject to such Post-Spin Issuer RSU, with any performance conditions applicable to such Post-Spin Issuer RSU deemed achieved at 100%, and (ii) the Merger Consideration, less any withholding taxes.
F4: In connection with the Distribution, each outstanding option to purchase common shares of the Issuer was adjusted such that such option became an option to acquire SpinCo common shares and an option to acquire Common Shares (each such option, a "Post-Spin Issuer Option"). At the effective time of the Merger, each outstanding Post-Spin Issuer Option was automatically cancelled in exchange for the right to receive (without interest) an amount in cash equal to the product of (i) the excess, if any, of the Merger Consideration over the exercise price per Common Share of such Post-Spin Issuer Option and (ii) the number of Common Shares subject to such Post-Spin Issuer Option, less any withholding taxes.
Social Capital Suvretta Holdings Corp. II
Report date August 16, 2021 · Filed August 16, 2021
Jointly reported with SCS Sponsor II LLC, Palihapitiya Chamath, Cowen Aaron, ChaChaCha DNA II, LLC
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class B ordinary sharesSEC Table II · derivative / convertible security | Direct | 6,220,000 |
Reported balance
After 2021-08-16 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2021-08-16 · Disposition to issuer · Disposed 75,000 · Balance 6,220,000 F1: As described in the issuer's registration statement on Form S-1 (File No. 333-256724) under the heading "Description of Securities--Founder Shares," the Class B ordinary shares, par value $0.0001 per share, of the issuer will automatically convert into Class A ordinary shares, par value $0.0001 per share, of the issuer at the time of the issuer's initial business combination, or earlier at the option of the holder, on a one-for-one basis, subject to certain adjustment, and have no expiration date. F2: On August 16, 2021, SCS Sponsor II LLC forfeited at no cost 75,000 shares of Class B ordinary shares of the issuer in connection with the election by the underwriters of the issuer's initial public offering to decline to exercise in full their option to purchase additional Class A ordinary shares. F3: The reporting owner, SCS Sponsor II LLC (the "Sponsor"), in whose name the securities reported herein are held, is managed by its managers, Chamath Palihapitiya and Kishan Mehta. A majority of the voting interests of the Sponsor are held by ChaChaCha DNA II, LLC ("ChaChaCha"), which is controlled by Mr. Palihapitiya. Messrs. Mehta and Cowen may be deemed to control the other member of the Sponsor. Messrs. Palihapitiya, Mehta and Cowen and ChaChaCha may be deemed to beneficially own shares held by the Sponsor by virtue of their direct or indirect interests in the Sponsor or their shared control over the Sponsor, as the case may be. Each of Mr. Palihapitiya, Mr. Mehta, ChaChaCha and Mr. Cowen disclaims beneficial ownership of the shares held by the Sponsor, except to the extent of such person's pecuniary interest therein. |
Filing footnotes · ownership attribution and instrument terms
F1: As described in the issuer's registration statement on Form S-1 (File No. 333-256724) under the heading "Description of Securities--Founder Shares," the Class B ordinary shares, par value $0.0001 per share, of the issuer will automatically convert into Class A ordinary shares, par value $0.0001 per share, of the issuer at the time of the issuer's initial business combination, or earlier at the option of the holder, on a one-for-one basis, subject to certain adjustment, and have no expiration date.
F2: On August 16, 2021, SCS Sponsor II LLC forfeited at no cost 75,000 shares of Class B ordinary shares of the issuer in connection with the election by the underwriters of the issuer's initial public offering to decline to exercise in full their option to purchase additional Class A ordinary shares.
F3: The reporting owner, SCS Sponsor II LLC (the "Sponsor"), in whose name the securities reported herein are held, is managed by its managers, Chamath Palihapitiya and Kishan Mehta. A majority of the voting interests of the Sponsor are held by ChaChaCha DNA II, LLC ("ChaChaCha"), which is controlled by Mr. Palihapitiya. Messrs. Mehta and Cowen may be deemed to control the other member of the Sponsor. Messrs. Palihapitiya, Mehta and Cowen and ChaChaCha may be deemed to beneficially own shares held by the Sponsor by virtue of their direct or indirect interests in the Sponsor or their shared control over the Sponsor, as the case may be. Each of Mr. Palihapitiya, Mr. Mehta, ChaChaCha and Mr. Cowen disclaims beneficial ownership of the shares held by the Sponsor, except to the extent of such person's pecuniary interest therein.
Social Capital Suvretta Holdings Corp. IV
Report date August 16, 2021 · Filed August 16, 2021
Jointly reported with SCS Sponsor IV LLC, Palihapitiya Chamath, Cowen Aaron, ChaChaCha DNA IV, LLC
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class B ordinary sharesSEC Table II · derivative / convertible security | Direct | 6,220,000 |
Reported balance
After 2021-08-16 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2021-08-16 · Disposition to issuer · Disposed 75,000 · Balance 6,220,000 F1: As described in the issuer's registration statement on Form S-1 (File No. 333-256727) under the heading "Description of Securities--Founder Shares," the Class B ordinary shares, par value $0.0001 per share, of the issuer will automatically convert into Class A ordinary shares, par value $0.0001 per share, of the issuer at the time of the issuer's initial business combination, or earlier at the option of the holder, on a one-for-one basis, subject to certain adjustment, and have no expiration date. F2: On August 16, 2021, SCS Sponsor IV LLC forfeited at no cost 75,000 shares of Class B common stock of the issuer in connection with the election by the underwriters of the issuer's initial public offering to decline to exercise in full their option to purchase additional Class A ordinary shares. F3: The reporting owner, SCS Sponsor IV LLC (the "Sponsor"), in whose name the securities reported herein are held, is managed by its managers, Chamath Palihapitiya and Kishan Mehta. A majority of the voting interests of the Sponsor are held by ChaChaCha DNA IV, LLC ("ChaChaCha"), which is controlled by Mr. Palihapitiya. Messrs. Mehta and Cowen may be deemed to control the other member of the Sponsor. Messrs. Palihapitiya, Mehta and Cowen and ChaChaCha may be deemed to beneficially own shares held by the Sponsor by virtue of their direct or indirect interests in the Sponsor or their shared control over the Sponsor, as the case may be. Each of Mr. Palihapitiya, Mr. Mehta, ChaChaCha and Mr. Cowen disclaims beneficial ownership of the shares held by the Sponsor, except to the extent of such person's pecuniary interest therein. |
Filing footnotes · ownership attribution and instrument terms
F1: As described in the issuer's registration statement on Form S-1 (File No. 333-256727) under the heading "Description of Securities--Founder Shares," the Class B ordinary shares, par value $0.0001 per share, of the issuer will automatically convert into Class A ordinary shares, par value $0.0001 per share, of the issuer at the time of the issuer's initial business combination, or earlier at the option of the holder, on a one-for-one basis, subject to certain adjustment, and have no expiration date.
F2: On August 16, 2021, SCS Sponsor IV LLC forfeited at no cost 75,000 shares of Class B common stock of the issuer in connection with the election by the underwriters of the issuer's initial public offering to decline to exercise in full their option to purchase additional Class A ordinary shares.
F3: The reporting owner, SCS Sponsor IV LLC (the "Sponsor"), in whose name the securities reported herein are held, is managed by its managers, Chamath Palihapitiya and Kishan Mehta. A majority of the voting interests of the Sponsor are held by ChaChaCha DNA IV, LLC ("ChaChaCha"), which is controlled by Mr. Palihapitiya. Messrs. Mehta and Cowen may be deemed to control the other member of the Sponsor. Messrs. Palihapitiya, Mehta and Cowen and ChaChaCha may be deemed to beneficially own shares held by the Sponsor by virtue of their direct or indirect interests in the Sponsor or their shared control over the Sponsor, as the case may be. Each of Mr. Palihapitiya, Mr. Mehta, ChaChaCha and Mr. Cowen disclaims beneficial ownership of the shares held by the Sponsor, except to the extent of such person's pecuniary interest therein.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
PROKIDNEY CORP.
Report date July 11, 2022 · Filed July 13, 2022
Jointly reported with SCS Sponsor III LLC, Cowen Aaron, ChaChaCha DNA III, LLC
Section 16 reporting ended · disclosed 2022-07-13. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class A ordinary sharesSEC Table I · non-derivative | Direct | 6,860,000 |
Reported balance
After 2022-07-11 transaction · row 1
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 1 · 2022-07-11 · Exercise / conversion · Acquired 6,220,000 · Balance 6,860,000 F1: The Class B ordinary shares held by the reporting owner, SCS Sponsor III LLC (the "Sponsor"), converted to Class A ordinary shares on a one-for-one basis upon the consummation of the business combination between the issuer and ProKidney LP. F2: The Sponsor is managed by its managers, Chamath Palihapitiya and Kishan Mehta. A majority of the voting interests of the Sponsor are held by SC SPAC Holdings LLC, the successor by merger to ChaChaCha DNA III, LLC ("SC SPAC Holdings"). Messrs. Mehta and Cowen may be deemed to control the other member of the Sponsor. Messrs. Mehta and Cowen and SC SPAC Holdings may be deemed to beneficially own shares held by the Sponsor by virtue of their direct or indirect interests in the Sponsor or their shared control over the Sponsor, as the case may be. |
| Class A ordinary sharesSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2022-07-11 transaction · row 2
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 2 · 2022-07-11 · Other · Disposed 6,860,000 · Balance 0 F3: Represents the distribution for no consideration by the Sponsor of 6,860,000 Class A ordinary shares to its members pro rata in accordance with their respective interests. |
| Class B ordinary sharesSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2022-07-11 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2022-07-11 · Exercise / conversion · Disposed 6,220,000 · Balance 0 F4: The Class B ordinary shares were automatically convertible into Class A ordinary shares at the time of the issuer's initial business combination, or earlier at the option of the holder, on a one-for-one basis, subject to certain adjustments, and had no expiration date. F1: The Class B ordinary shares held by the reporting owner, SCS Sponsor III LLC (the "Sponsor"), converted to Class A ordinary shares on a one-for-one basis upon the consummation of the business combination between the issuer and ProKidney LP. F2: The Sponsor is managed by its managers, Chamath Palihapitiya and Kishan Mehta. A majority of the voting interests of the Sponsor are held by SC SPAC Holdings LLC, the successor by merger to ChaChaCha DNA III, LLC ("SC SPAC Holdings"). Messrs. Mehta and Cowen may be deemed to control the other member of the Sponsor. Messrs. Mehta and Cowen and SC SPAC Holdings may be deemed to beneficially own shares held by the Sponsor by virtue of their direct or indirect interests in the Sponsor or their shared control over the Sponsor, as the case may be. |
Filing footnotes · ownership attribution and instrument terms
F1: The Class B ordinary shares held by the reporting owner, SCS Sponsor III LLC (the "Sponsor"), converted to Class A ordinary shares on a one-for-one basis upon the consummation of the business combination between the issuer and ProKidney LP.
F2: The Sponsor is managed by its managers, Chamath Palihapitiya and Kishan Mehta. A majority of the voting interests of the Sponsor are held by SC SPAC Holdings LLC, the successor by merger to ChaChaCha DNA III, LLC ("SC SPAC Holdings"). Messrs. Mehta and Cowen may be deemed to control the other member of the Sponsor. Messrs. Mehta and Cowen and SC SPAC Holdings may be deemed to beneficially own shares held by the Sponsor by virtue of their direct or indirect interests in the Sponsor or their shared control over the Sponsor, as the case may be.
F3: Represents the distribution for no consideration by the Sponsor of 6,860,000 Class A ordinary shares to its members pro rata in accordance with their respective interests.
F4: The Class B ordinary shares were automatically convertible into Class A ordinary shares at the time of the issuer's initial business combination, or earlier at the option of the holder, on a one-for-one basis, subject to certain adjustments, and had no expiration date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| April 28, 2026 Filed May 1, 2026 00:09 UTC | Biohaven Ltd. BHVN · Entity 4379 | GrantStock Options (Right to buy) · Derivative | 68,693 | $0.00 Strike: $9.61 | $0.00 |
DisclosureSEC source: 0001850520-26-000005 · wk-form4_1777594180.xml · derivative · entry 1 Mehta Kishan · CIK 0001850520 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 68,693 Underlying: Common Shares · 68,693 shares Expires 2036-04-28 F1 · derivative.exercise_date: The shares subject to this stock option will vest in full on the earlier of (a) April 28, 2027 or (b) the date of the 2027 Annual Meeting of Shareholders, in each case subject to the Reporting Person's continuous service with the Issuer through such vesting date. Read SEC document |
| March 17, 2026 Filed Mar 19, 2026 22:17 UTC | Biohaven Ltd. BHVN · Entity 4379 | GiftCommon Shares | 17,342 | $0.00 | $0.00 |
DisclosureSEC source: 0001850520-26-000003 · wk-form4_1773958666.xml · nonDerivative · entry 2 Mehta Kishan · CIK 0001850520 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By Kishen Mehta 21 Family Irrevocable Trust Disclosed balance after: 17,342 F1 · ownership.nature: These Common Shares are held in a trust for the benefit of the Reporting Person's family members, excluding the Reporting Person. The Reporting Person's spouse and the spouse's sibling are co-trustees of the trust. The Reporting Person disclaims beneficial ownership of these securities, and the inclusion of the securities held by the trust in this report and prior Section 16 filings by the Reporting Person is not an admission that the reporting person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose. Read SEC document |
| March 17, 2026 Filed Mar 19, 2026 22:17 UTC | Biohaven Ltd. BHVN · Entity 4379 | GiftCommon Shares | 17,342 | $0.00 | $0.00 |
DisclosureSEC source: 0001850520-26-000003 · wk-form4_1773958666.xml · nonDerivative · entry 1 Mehta Kishan · CIK 0001850520 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,320 Read SEC document |
| December 01, 2025 Filed Dec 3, 2025 16:19 UTC | Benitec Biopharma Inc. BNTC · Entity 5596 | GrantOptions (right to buy) · Derivative | 35,000 | $0.00 Strike: $12.23 | $0.00 |
DisclosureSEC source: 0001012975-25-000850 · form4.xml · derivative · entry 1 Mehta Kishan · CIK 0001850520 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 35,000 Underlying: Common Stock · 35,000 shares Expires 2035-12-01 F1 · shares: Consists of options to purchase shares of the Issuer's common stock awarded to Mr. Mehta in connection with his role as a member of the Issuer's Board of Directors. Mr. Mehta, as Portfolio Manager for Averill Master Fund, Ltd. and Averill Madison Master Fund, Ltd (the "Funds") is holding such options for the benefit of the Funds, and as such Mr. Mehta disclaims beneficial ownership of such options. The Funds, and Suvretta Capital Management, LLC ("Suvretta Capital"), the investment manager of the Funds, may be deemed to have an indirect pecuniary interest in such options because Suvretta Capital has rights to receive the benefit of director compensation provided in respect of Mr. Mehta's board service. F2 · derivative.exercise_date: The stock options will vest on the earlier of the Issuer's next annual stockholders' meeting or December 1, 2026. Read SEC document |
| May 05, 2025 Filed May 7, 2025 21:13 UTC | Biohaven Ltd. BHVN · Entity 4379 | GrantStock Options (Right to buy) · Derivative | 31,716 | $0.00 Strike: $22.62 | $0.00 |
DisclosureSEC source: 0001935979-25-000044 · wk-form4_1746652427.xml · derivative · entry 1 Mehta Kishan · CIK 0001850520 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 31,716 Underlying: Common Shares · 31,716 shares Expires 2035-05-05 F1 · derivative.exercise_date: The shares subject to this stock option will vest in full on the earlier of (a) May 5, 2026 or (b) the date of the 2026 Annual Meeting of Shareholders, in each case subject to the Reporting Person's continuous service with the Issuer through such vesting date. Read SEC document |
| December 09, 2024 Filed Dec 11, 2024 18:48 UTC | Benitec Biopharma Inc. BNTC · Entity 5596 | GrantOptions (right to buy) · Derivative | 35,000 | $0.00 Strike: $12.18 | $0.00 |
DisclosureSEC source: 0001062993-24-020503 · form4.xml · derivative · entry 1 Mehta Kishan · CIK 0001850520 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 35,000 Underlying: Common Stock · 35,000 shares Expires 2034-12-09 F1 · shares: Consists of options to purchase shares of the Issuer's common stock awarded to Mr. Mehta in connection with his role as a member of the Issuer's Board of Directors. Mr. Mehta, as Portfolio Manager for Averill Master Fund, Ltd. and Averill Madison Master Fund, Ltd (the "Funds") is holding such options for the benefit of the Funds, and as such Mr. Mehta disclaims beneficial ownership of such options. The Funds, and Suvretta Capital Management, LLC ("Suvretta Capital"), the investment manager of the Funds, may be deemed to have an indirect pecuniary interest in such options because Suvretta Capital has rights to receive the benefit of director compensation provided in respect of Mr. Mehta's board service. F2 · derivative.exercise_date: The stock options will vest on the earlier of the Issuer's next annual stockholders' meeting or December 9, 2025. Read SEC document |
| April 30, 2024 Filed May 2, 2024 23:34 UTC | Biohaven Ltd. BHVN · Entity 4379 | GrantStock Option (Right to Buy) · Derivative | 16,592 | $0.00 Strike: $38.80 | $0.00 |
DisclosureSEC source: 0001562180-24-003755 · primarydocument.xml · derivative · entry 1 Mehta Kishan · CIK 0001850520 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,592 Underlying: Common Shares · 16,592 shares Expires 2034-04-30 F1 · derivative.exercise_date: The shares subject to this stock option will vest in full on the earlier of (a) April 30, 2025 or (b) the date of the 2025 Annual Meeting of Shareholders, in each case subject to the Reporting Person's continuous service with the Issuer through such vesting date. Read SEC document |
| May 02, 2023 Filed May 4, 2023 21:52 UTC | Biohaven Ltd. BHVN · Entity 4379 | GrantStock Option (Right to Buy) · Derivative | 52,906 | $0.00 Strike: $13.20 | $0.00 |
DisclosureSEC source: 0001562180-23-003945 · primarydocument.xml · derivative · entry 1 Mehta Kishan · CIK 0001850520 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 52,906 Underlying: Common Shares · 52,906 shares Expires 2033-05-02 F1 · derivative.exercise_date: The shares subject to this stock option will vest in full on the earlier of (a) May 2, 2024 or (b) the date of the 2024 Annual Meeting of Shareholders, in each case subject to the Reporting Person's continuous service with the Issuer through such vesting date. Read SEC document |
| October 03, 2022 Filed Oct 3, 2022 20:27 UTC | Biohaven Pharmaceutical Holding Co Ltd. BHVN · Entity 123269 | Disposition to issuerStock Options (Right to Buy) · Derivative | 20,000 | Not disclosed Strike: $36.64 | Not disclosed |
DisclosureSEC source: 0001562180-22-006958 · primarydocument.xml · derivative · entry 6 Mehta Kishan · CIK 0001850520 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Shares · 20,000 shares Expires 2029-01-17 F4 · derivative.exercise_price: In connection with the Distribution, each outstanding option to purchase common shares of the Issuer was adjusted such that such option became an option to acquire SpinCo common shares and an option to acquire Common Shares (each such option, a "Post-Spin Issuer Option"). At the effective time of the Merger, each outstanding Post-Spin Issuer Option was automatically cancelled in exchange for the right to receive (without interest) an amount in cash equal to the product of (i) the excess, if any, of the Merger Consideration over the exercise price per Common Share of such Post-Spin Issuer Option and (ii) the number of Common Shares subject to such Post-Spin Issuer Option, less any withholding taxes. F4 · shares: In connection with the Distribution, each outstanding option to purchase common shares of the Issuer was adjusted such that such option became an option to acquire SpinCo common shares and an option to acquire Common Shares (each such option, a "Post-Spin Issuer Option"). At the effective time of the Merger, each outstanding Post-Spin Issuer Option was automatically cancelled in exchange for the right to receive (without interest) an amount in cash equal to the product of (i) the excess, if any, of the Merger Consideration over the exercise price per Common Share of such Post-Spin Issuer Option and (ii) the number of Common Shares subject to such Post-Spin Issuer Option, less any withholding taxes. F4 · price: In connection with the Distribution, each outstanding option to purchase common shares of the Issuer was adjusted such that such option became an option to acquire SpinCo common shares and an option to acquire Common Shares (each such option, a "Post-Spin Issuer Option"). At the effective time of the Merger, each outstanding Post-Spin Issuer Option was automatically cancelled in exchange for the right to receive (without interest) an amount in cash equal to the product of (i) the excess, if any, of the Merger Consideration over the exercise price per Common Share of such Post-Spin Issuer Option and (ii) the number of Common Shares subject to such Post-Spin Issuer Option, less any withholding taxes. F4 · derivative.exercise_date: In connection with the Distribution, each outstanding option to purchase common shares of the Issuer was adjusted such that such option became an option to acquire SpinCo common shares and an option to acquire Common Shares (each such option, a "Post-Spin Issuer Option"). At the effective time of the Merger, each outstanding Post-Spin Issuer Option was automatically cancelled in exchange for the right to receive (without interest) an amount in cash equal to the product of (i) the excess, if any, of the Merger Consideration over the exercise price per Common Share of such Post-Spin Issuer Option and (ii) the number of Common Shares subject to such Post-Spin Issuer Option, less any withholding taxes. F4 · derivative.expiration_date: In connection with the Distribution, each outstanding option to purchase common shares of the Issuer was adjusted such that such option became an option to acquire SpinCo common shares and an option to acquire Common Shares (each such option, a "Post-Spin Issuer Option"). At the effective time of the Merger, each outstanding Post-Spin Issuer Option was automatically cancelled in exchange for the right to receive (without interest) an amount in cash equal to the product of (i) the excess, if any, of the Merger Consideration over the exercise price per Common Share of such Post-Spin Issuer Option and (ii) the number of Common Shares subject to such Post-Spin Issuer Option, less any withholding taxes. Read SEC document |
| October 03, 2022 Filed Oct 3, 2022 20:27 UTC | Biohaven Pharmaceutical Holding Co Ltd. BHVN · Entity 123269 | Disposition to issuerStock Options (Right to Buy) · Derivative | 15,000 | Not disclosed Strike: $50.85 | Not disclosed |
DisclosureSEC source: 0001562180-22-006958 · primarydocument.xml · derivative · entry 5 Mehta Kishan · CIK 0001850520 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Shares · 15,000 shares Expires 2029-12-18 F4 · derivative.exercise_price: In connection with the Distribution, each outstanding option to purchase common shares of the Issuer was adjusted such that such option became an option to acquire SpinCo common shares and an option to acquire Common Shares (each such option, a "Post-Spin Issuer Option"). At the effective time of the Merger, each outstanding Post-Spin Issuer Option was automatically cancelled in exchange for the right to receive (without interest) an amount in cash equal to the product of (i) the excess, if any, of the Merger Consideration over the exercise price per Common Share of such Post-Spin Issuer Option and (ii) the number of Common Shares subject to such Post-Spin Issuer Option, less any withholding taxes. F4 · shares: In connection with the Distribution, each outstanding option to purchase common shares of the Issuer was adjusted such that such option became an option to acquire SpinCo common shares and an option to acquire Common Shares (each such option, a "Post-Spin Issuer Option"). At the effective time of the Merger, each outstanding Post-Spin Issuer Option was automatically cancelled in exchange for the right to receive (without interest) an amount in cash equal to the product of (i) the excess, if any, of the Merger Consideration over the exercise price per Common Share of such Post-Spin Issuer Option and (ii) the number of Common Shares subject to such Post-Spin Issuer Option, less any withholding taxes. F4 · price: In connection with the Distribution, each outstanding option to purchase common shares of the Issuer was adjusted such that such option became an option to acquire SpinCo common shares and an option to acquire Common Shares (each such option, a "Post-Spin Issuer Option"). At the effective time of the Merger, each outstanding Post-Spin Issuer Option was automatically cancelled in exchange for the right to receive (without interest) an amount in cash equal to the product of (i) the excess, if any, of the Merger Consideration over the exercise price per Common Share of such Post-Spin Issuer Option and (ii) the number of Common Shares subject to such Post-Spin Issuer Option, less any withholding taxes. F4 · derivative.exercise_date: In connection with the Distribution, each outstanding option to purchase common shares of the Issuer was adjusted such that such option became an option to acquire SpinCo common shares and an option to acquire Common Shares (each such option, a "Post-Spin Issuer Option"). At the effective time of the Merger, each outstanding Post-Spin Issuer Option was automatically cancelled in exchange for the right to receive (without interest) an amount in cash equal to the product of (i) the excess, if any, of the Merger Consideration over the exercise price per Common Share of such Post-Spin Issuer Option and (ii) the number of Common Shares subject to such Post-Spin Issuer Option, less any withholding taxes. F4 · derivative.expiration_date: In connection with the Distribution, each outstanding option to purchase common shares of the Issuer was adjusted such that such option became an option to acquire SpinCo common shares and an option to acquire Common Shares (each such option, a "Post-Spin Issuer Option"). At the effective time of the Merger, each outstanding Post-Spin Issuer Option was automatically cancelled in exchange for the right to receive (without interest) an amount in cash equal to the product of (i) the excess, if any, of the Merger Consideration over the exercise price per Common Share of such Post-Spin Issuer Option and (ii) the number of Common Shares subject to such Post-Spin Issuer Option, less any withholding taxes. Read SEC document |
| October 03, 2022 Filed Oct 3, 2022 20:27 UTC | Biohaven Pharmaceutical Holding Co Ltd. BHVN · Entity 123269 | Disposition to issuerStock Options (Right to Buy) · Derivative | 13,004 | Not disclosed Strike: $90.91 | Not disclosed |
DisclosureSEC source: 0001562180-22-006958 · primarydocument.xml · derivative · entry 4 Mehta Kishan · CIK 0001850520 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Shares · 13,004 shares Expires 2031-06-15 F4 · derivative.exercise_price: In connection with the Distribution, each outstanding option to purchase common shares of the Issuer was adjusted such that such option became an option to acquire SpinCo common shares and an option to acquire Common Shares (each such option, a "Post-Spin Issuer Option"). At the effective time of the Merger, each outstanding Post-Spin Issuer Option was automatically cancelled in exchange for the right to receive (without interest) an amount in cash equal to the product of (i) the excess, if any, of the Merger Consideration over the exercise price per Common Share of such Post-Spin Issuer Option and (ii) the number of Common Shares subject to such Post-Spin Issuer Option, less any withholding taxes. F4 · shares: In connection with the Distribution, each outstanding option to purchase common shares of the Issuer was adjusted such that such option became an option to acquire SpinCo common shares and an option to acquire Common Shares (each such option, a "Post-Spin Issuer Option"). At the effective time of the Merger, each outstanding Post-Spin Issuer Option was automatically cancelled in exchange for the right to receive (without interest) an amount in cash equal to the product of (i) the excess, if any, of the Merger Consideration over the exercise price per Common Share of such Post-Spin Issuer Option and (ii) the number of Common Shares subject to such Post-Spin Issuer Option, less any withholding taxes. F4 · price: In connection with the Distribution, each outstanding option to purchase common shares of the Issuer was adjusted such that such option became an option to acquire SpinCo common shares and an option to acquire Common Shares (each such option, a "Post-Spin Issuer Option"). At the effective time of the Merger, each outstanding Post-Spin Issuer Option was automatically cancelled in exchange for the right to receive (without interest) an amount in cash equal to the product of (i) the excess, if any, of the Merger Consideration over the exercise price per Common Share of such Post-Spin Issuer Option and (ii) the number of Common Shares subject to such Post-Spin Issuer Option, less any withholding taxes. F4 · derivative.exercise_date: In connection with the Distribution, each outstanding option to purchase common shares of the Issuer was adjusted such that such option became an option to acquire SpinCo common shares and an option to acquire Common Shares (each such option, a "Post-Spin Issuer Option"). At the effective time of the Merger, each outstanding Post-Spin Issuer Option was automatically cancelled in exchange for the right to receive (without interest) an amount in cash equal to the product of (i) the excess, if any, of the Merger Consideration over the exercise price per Common Share of such Post-Spin Issuer Option and (ii) the number of Common Shares subject to such Post-Spin Issuer Option, less any withholding taxes. F4 · derivative.expiration_date: In connection with the Distribution, each outstanding option to purchase common shares of the Issuer was adjusted such that such option became an option to acquire SpinCo common shares and an option to acquire Common Shares (each such option, a "Post-Spin Issuer Option"). At the effective time of the Merger, each outstanding Post-Spin Issuer Option was automatically cancelled in exchange for the right to receive (without interest) an amount in cash equal to the product of (i) the excess, if any, of the Merger Consideration over the exercise price per Common Share of such Post-Spin Issuer Option and (ii) the number of Common Shares subject to such Post-Spin Issuer Option, less any withholding taxes. Read SEC document |
| October 03, 2022 Filed Oct 3, 2022 20:27 UTC | Biohaven Pharmaceutical Holding Co Ltd. BHVN · Entity 123269 | Disposition to issuerStock Options (Right to Buy) · Derivative | 8,239 | Not disclosed Strike: $95.33 | Not disclosed |
DisclosureSEC source: 0001562180-22-006958 · primarydocument.xml · derivative · entry 3 Mehta Kishan · CIK 0001850520 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Shares · 8,239 shares Expires 2032-04-28 F4 · derivative.exercise_price: In connection with the Distribution, each outstanding option to purchase common shares of the Issuer was adjusted such that such option became an option to acquire SpinCo common shares and an option to acquire Common Shares (each such option, a "Post-Spin Issuer Option"). At the effective time of the Merger, each outstanding Post-Spin Issuer Option was automatically cancelled in exchange for the right to receive (without interest) an amount in cash equal to the product of (i) the excess, if any, of the Merger Consideration over the exercise price per Common Share of such Post-Spin Issuer Option and (ii) the number of Common Shares subject to such Post-Spin Issuer Option, less any withholding taxes. F4 · shares: In connection with the Distribution, each outstanding option to purchase common shares of the Issuer was adjusted such that such option became an option to acquire SpinCo common shares and an option to acquire Common Shares (each such option, a "Post-Spin Issuer Option"). At the effective time of the Merger, each outstanding Post-Spin Issuer Option was automatically cancelled in exchange for the right to receive (without interest) an amount in cash equal to the product of (i) the excess, if any, of the Merger Consideration over the exercise price per Common Share of such Post-Spin Issuer Option and (ii) the number of Common Shares subject to such Post-Spin Issuer Option, less any withholding taxes. F4 · price: In connection with the Distribution, each outstanding option to purchase common shares of the Issuer was adjusted such that such option became an option to acquire SpinCo common shares and an option to acquire Common Shares (each such option, a "Post-Spin Issuer Option"). At the effective time of the Merger, each outstanding Post-Spin Issuer Option was automatically cancelled in exchange for the right to receive (without interest) an amount in cash equal to the product of (i) the excess, if any, of the Merger Consideration over the exercise price per Common Share of such Post-Spin Issuer Option and (ii) the number of Common Shares subject to such Post-Spin Issuer Option, less any withholding taxes. F4 · derivative.exercise_date: In connection with the Distribution, each outstanding option to purchase common shares of the Issuer was adjusted such that such option became an option to acquire SpinCo common shares and an option to acquire Common Shares (each such option, a "Post-Spin Issuer Option"). At the effective time of the Merger, each outstanding Post-Spin Issuer Option was automatically cancelled in exchange for the right to receive (without interest) an amount in cash equal to the product of (i) the excess, if any, of the Merger Consideration over the exercise price per Common Share of such Post-Spin Issuer Option and (ii) the number of Common Shares subject to such Post-Spin Issuer Option, less any withholding taxes. F4 · derivative.expiration_date: In connection with the Distribution, each outstanding option to purchase common shares of the Issuer was adjusted such that such option became an option to acquire SpinCo common shares and an option to acquire Common Shares (each such option, a "Post-Spin Issuer Option"). At the effective time of the Merger, each outstanding Post-Spin Issuer Option was automatically cancelled in exchange for the right to receive (without interest) an amount in cash equal to the product of (i) the excess, if any, of the Merger Consideration over the exercise price per Common Share of such Post-Spin Issuer Option and (ii) the number of Common Shares subject to such Post-Spin Issuer Option, less any withholding taxes. Read SEC document |
| October 03, 2022 Filed Oct 3, 2022 20:27 UTC | Biohaven Pharmaceutical Holding Co Ltd. BHVN · Entity 123269 | Disposition to issuerRestricted Share Unit Award · Derivative | 1,875 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001562180-22-006958 · primarydocument.xml · derivative · entry 2 Mehta Kishan · CIK 0001850520 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Shares · 1,875 shares Expires not disclosed F3 · derivative.exercise_price: In connection with the distribution ("Distribution") by the Issuer to holders of its common shares of all the outstanding common shares of Biohaven Ltd. ("SpinCo"), each outstanding restricted share unit of the Issuer was adjusted such that such restricted share unit became a restricted share unit in respect of common shares of SpinCo and a restricted share unit in respect of Common Shares (each such restricted share unit, a "Post-Spin Issuer RSU"). At the effective time of the Merger, each outstanding Post-Spin Issuer RSU was automatically cancelled in exchange for the right to receive (without interest) an amount in cash equal to the product of (i) the number of Common Shares subject to such Post-Spin Issuer RSU, with any performance conditions applicable to such Post-Spin Issuer RSU deemed achieved at 100%, and (ii) the Merger Consideration, less any withholding taxes. F3 · shares: In connection with the distribution ("Distribution") by the Issuer to holders of its common shares of all the outstanding common shares of Biohaven Ltd. ("SpinCo"), each outstanding restricted share unit of the Issuer was adjusted such that such restricted share unit became a restricted share unit in respect of common shares of SpinCo and a restricted share unit in respect of Common Shares (each such restricted share unit, a "Post-Spin Issuer RSU"). At the effective time of the Merger, each outstanding Post-Spin Issuer RSU was automatically cancelled in exchange for the right to receive (without interest) an amount in cash equal to the product of (i) the number of Common Shares subject to such Post-Spin Issuer RSU, with any performance conditions applicable to such Post-Spin Issuer RSU deemed achieved at 100%, and (ii) the Merger Consideration, less any withholding taxes. F3 · price: In connection with the distribution ("Distribution") by the Issuer to holders of its common shares of all the outstanding common shares of Biohaven Ltd. ("SpinCo"), each outstanding restricted share unit of the Issuer was adjusted such that such restricted share unit became a restricted share unit in respect of common shares of SpinCo and a restricted share unit in respect of Common Shares (each such restricted share unit, a "Post-Spin Issuer RSU"). At the effective time of the Merger, each outstanding Post-Spin Issuer RSU was automatically cancelled in exchange for the right to receive (without interest) an amount in cash equal to the product of (i) the number of Common Shares subject to such Post-Spin Issuer RSU, with any performance conditions applicable to such Post-Spin Issuer RSU deemed achieved at 100%, and (ii) the Merger Consideration, less any withholding taxes. F3 · derivative.exercise_date: In connection with the distribution ("Distribution") by the Issuer to holders of its common shares of all the outstanding common shares of Biohaven Ltd. ("SpinCo"), each outstanding restricted share unit of the Issuer was adjusted such that such restricted share unit became a restricted share unit in respect of common shares of SpinCo and a restricted share unit in respect of Common Shares (each such restricted share unit, a "Post-Spin Issuer RSU"). At the effective time of the Merger, each outstanding Post-Spin Issuer RSU was automatically cancelled in exchange for the right to receive (without interest) an amount in cash equal to the product of (i) the number of Common Shares subject to such Post-Spin Issuer RSU, with any performance conditions applicable to such Post-Spin Issuer RSU deemed achieved at 100%, and (ii) the Merger Consideration, less any withholding taxes. F3 · derivative.expiration_date: In connection with the distribution ("Distribution") by the Issuer to holders of its common shares of all the outstanding common shares of Biohaven Ltd. ("SpinCo"), each outstanding restricted share unit of the Issuer was adjusted such that such restricted share unit became a restricted share unit in respect of common shares of SpinCo and a restricted share unit in respect of Common Shares (each such restricted share unit, a "Post-Spin Issuer RSU"). At the effective time of the Merger, each outstanding Post-Spin Issuer RSU was automatically cancelled in exchange for the right to receive (without interest) an amount in cash equal to the product of (i) the number of Common Shares subject to such Post-Spin Issuer RSU, with any performance conditions applicable to such Post-Spin Issuer RSU deemed achieved at 100%, and (ii) the Merger Consideration, less any withholding taxes. Read SEC document |
| October 03, 2022 Filed Oct 3, 2022 20:27 UTC | Biohaven Pharmaceutical Holding Co Ltd. BHVN · Entity 123269 | Disposition to issuerCommon Shares | 10,640 | $148.50 | $1,580,040.00 |
DisclosureSEC source: 0001562180-22-006958 · primarydocument.xml · nonDerivative · entry 1 Mehta Kishan · CIK 0001850520 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: Under the Agreement and Plan of Merger, dated as of May 9, 2022 (the "Merger Agreement"), by and among the Issuer, Pfizer Inc. ("Pfizer") and a wholly owned subsidiary of Pfizer ("Merger Sub"), following satisfaction or waiver of the closing conditions set forth in the Merger Agreement, on October 3, 2022 Merger Sub merged with and into the Issuer with the Issuer surviving as the surviving company (the "Merger"). F2 · price: In the Merger, each common share of the Issuer (each, a "Common Share") outstanding immediately prior to the effective time of the Merger (other than certain excluded shares pursuant to the terms of the Merger Agreement), was converted into the right to receive the merger consideration in cash of $148.50, without interest, less any withholding taxes (the "Merger Consideration"). Read SEC document |
| October 03, 2022 Filed Oct 5, 2022 21:39 UTC | Biohaven Ltd. BHVN · Entity 4379 | GrantStock Options (Right to buy) · Derivative | 125,000 | $0.00 Strike: $7.00 | $0.00 |
DisclosureSEC source: 0001562180-22-007081 · primarydocument.xml · derivative · entry 16 Mehta Kishan · CIK 0001850520 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 125,000 Underlying: Common Shares · 125,000 shares Expires 2032-10-04 F5 · derivative.exercise_date: The shares underlying this option vest in four equal installments on October 3, 2022, 2023, 2024, and 2025, subject to the Reporting Person's continuous service with the Issuer at each vesting date. Read SEC document |
| October 03, 2022 Filed Oct 5, 2022 21:39 UTC | Biohaven Ltd. BHVN · Entity 4379 | Exercise / conversionStock Options (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $1.86 | $0.00 |
DisclosureSEC source: 0001562180-22-007081 · primarydocument.xml · derivative · entry 15 Mehta Kishan · CIK 0001850520 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Shares · 10,000 shares Expires 2029-01-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: Effective as of the Distribution, each outstanding option to purchase common shares of RemainCo was adjusted so that such option became an option to acquire Common Shares and an option to acquire RemainCo common shares. As a result, the Reporting Person acquired options to acquire the Issuer's Common Shares in an amount determined in accordance with the Separation Agreement. F4 · derivative.expiration_date: Effective as of the Distribution, each outstanding option to purchase common shares of RemainCo was adjusted so that such option became an option to acquire Common Shares and an option to acquire RemainCo common shares. As a result, the Reporting Person acquired options to acquire the Issuer's Common Shares in an amount determined in accordance with the Separation Agreement. Read SEC document |
| October 03, 2022 Filed Oct 5, 2022 21:39 UTC | Biohaven Ltd. BHVN · Entity 4379 | Exercise / conversionStock Options (Right to Buy) · Derivative | 7,500 | $0.00 Strike: $2.58 | $0.00 |
DisclosureSEC source: 0001562180-22-007081 · primarydocument.xml · derivative · entry 14 Mehta Kishan · CIK 0001850520 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Shares · 7,500 shares Expires 2029-12-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: Effective as of the Distribution, each outstanding option to purchase common shares of RemainCo was adjusted so that such option became an option to acquire Common Shares and an option to acquire RemainCo common shares. As a result, the Reporting Person acquired options to acquire the Issuer's Common Shares in an amount determined in accordance with the Separation Agreement. F4 · derivative.expiration_date: Effective as of the Distribution, each outstanding option to purchase common shares of RemainCo was adjusted so that such option became an option to acquire Common Shares and an option to acquire RemainCo common shares. As a result, the Reporting Person acquired options to acquire the Issuer's Common Shares in an amount determined in accordance with the Separation Agreement. Read SEC document |
| October 03, 2022 Filed Oct 5, 2022 21:39 UTC | Biohaven Ltd. BHVN · Entity 4379 | Exercise / conversionStock Options (Right to Buy) · Derivative | 6,502 | $0.00 Strike: $4.61 | $0.00 |
DisclosureSEC source: 0001562180-22-007081 · primarydocument.xml · derivative · entry 13 Mehta Kishan · CIK 0001850520 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Shares · 6,502 shares Expires 2031-06-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: Effective as of the Distribution, each outstanding option to purchase common shares of RemainCo was adjusted so that such option became an option to acquire Common Shares and an option to acquire RemainCo common shares. As a result, the Reporting Person acquired options to acquire the Issuer's Common Shares in an amount determined in accordance with the Separation Agreement. F4 · derivative.expiration_date: Effective as of the Distribution, each outstanding option to purchase common shares of RemainCo was adjusted so that such option became an option to acquire Common Shares and an option to acquire RemainCo common shares. As a result, the Reporting Person acquired options to acquire the Issuer's Common Shares in an amount determined in accordance with the Separation Agreement. Read SEC document |
| October 03, 2022 Filed Oct 5, 2022 21:39 UTC | Biohaven Ltd. BHVN · Entity 4379 | Exercise / conversionStock Options (Right to Buy) · Derivative | 4,119 | $0.00 Strike: $4.84 | $0.00 |
DisclosureSEC source: 0001562180-22-007081 · primarydocument.xml · derivative · entry 12 Mehta Kishan · CIK 0001850520 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Shares · 4,119 shares Expires 2032-04-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: Effective as of the Distribution, each outstanding option to purchase common shares of RemainCo was adjusted so that such option became an option to acquire Common Shares and an option to acquire RemainCo common shares. As a result, the Reporting Person acquired options to acquire the Issuer's Common Shares in an amount determined in accordance with the Separation Agreement. F4 · derivative.expiration_date: Effective as of the Distribution, each outstanding option to purchase common shares of RemainCo was adjusted so that such option became an option to acquire Common Shares and an option to acquire RemainCo common shares. As a result, the Reporting Person acquired options to acquire the Issuer's Common Shares in an amount determined in accordance with the Separation Agreement. Read SEC document |
| October 03, 2022 Filed Oct 5, 2022 21:39 UTC | Biohaven Ltd. BHVN · Entity 4379 | OtherStock Options (Right to Buy) · Derivative | 10,000 | Not disclosed Strike: $1.86 | Not disclosed |
DisclosureSEC source: 0001562180-22-007081 · primarydocument.xml · derivative · entry 11 Mehta Kishan · CIK 0001850520 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Shares · 10,000 shares Expires 2029-01-17 F4 · derivative.exercise_price: Effective as of the Distribution, each outstanding option to purchase common shares of RemainCo was adjusted so that such option became an option to acquire Common Shares and an option to acquire RemainCo common shares. As a result, the Reporting Person acquired options to acquire the Issuer's Common Shares in an amount determined in accordance with the Separation Agreement. F4 · shares: Effective as of the Distribution, each outstanding option to purchase common shares of RemainCo was adjusted so that such option became an option to acquire Common Shares and an option to acquire RemainCo common shares. As a result, the Reporting Person acquired options to acquire the Issuer's Common Shares in an amount determined in accordance with the Separation Agreement. F4 · price: Effective as of the Distribution, each outstanding option to purchase common shares of RemainCo was adjusted so that such option became an option to acquire Common Shares and an option to acquire RemainCo common shares. As a result, the Reporting Person acquired options to acquire the Issuer's Common Shares in an amount determined in accordance with the Separation Agreement. F4 · derivative.exercise_date: Effective as of the Distribution, each outstanding option to purchase common shares of RemainCo was adjusted so that such option became an option to acquire Common Shares and an option to acquire RemainCo common shares. As a result, the Reporting Person acquired options to acquire the Issuer's Common Shares in an amount determined in accordance with the Separation Agreement. F4 · derivative.expiration_date: Effective as of the Distribution, each outstanding option to purchase common shares of RemainCo was adjusted so that such option became an option to acquire Common Shares and an option to acquire RemainCo common shares. As a result, the Reporting Person acquired options to acquire the Issuer's Common Shares in an amount determined in accordance with the Separation Agreement. Read SEC document |
| October 03, 2022 Filed Oct 5, 2022 21:39 UTC | Biohaven Ltd. BHVN · Entity 4379 | OtherStock Options (Right to Buy) · Derivative | 7,500 | Not disclosed Strike: $2.58 | Not disclosed |
DisclosureSEC source: 0001562180-22-007081 · primarydocument.xml · derivative · entry 10 Mehta Kishan · CIK 0001850520 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,500 Underlying: Common Shares · 7,500 shares Expires 2029-12-18 F4 · derivative.exercise_price: Effective as of the Distribution, each outstanding option to purchase common shares of RemainCo was adjusted so that such option became an option to acquire Common Shares and an option to acquire RemainCo common shares. As a result, the Reporting Person acquired options to acquire the Issuer's Common Shares in an amount determined in accordance with the Separation Agreement. F4 · shares: Effective as of the Distribution, each outstanding option to purchase common shares of RemainCo was adjusted so that such option became an option to acquire Common Shares and an option to acquire RemainCo common shares. As a result, the Reporting Person acquired options to acquire the Issuer's Common Shares in an amount determined in accordance with the Separation Agreement. F4 · price: Effective as of the Distribution, each outstanding option to purchase common shares of RemainCo was adjusted so that such option became an option to acquire Common Shares and an option to acquire RemainCo common shares. As a result, the Reporting Person acquired options to acquire the Issuer's Common Shares in an amount determined in accordance with the Separation Agreement. F4 · derivative.exercise_date: Effective as of the Distribution, each outstanding option to purchase common shares of RemainCo was adjusted so that such option became an option to acquire Common Shares and an option to acquire RemainCo common shares. As a result, the Reporting Person acquired options to acquire the Issuer's Common Shares in an amount determined in accordance with the Separation Agreement. F4 · derivative.expiration_date: Effective as of the Distribution, each outstanding option to purchase common shares of RemainCo was adjusted so that such option became an option to acquire Common Shares and an option to acquire RemainCo common shares. As a result, the Reporting Person acquired options to acquire the Issuer's Common Shares in an amount determined in accordance with the Separation Agreement. Read SEC document |
| October 03, 2022 Filed Oct 5, 2022 21:39 UTC | Biohaven Ltd. BHVN · Entity 4379 | OtherStock Options (Right to Buy) · Derivative | 6,502 | Not disclosed Strike: $4.61 | Not disclosed |
DisclosureSEC source: 0001562180-22-007081 · primarydocument.xml · derivative · entry 9 Mehta Kishan · CIK 0001850520 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,502 Underlying: Common Shares · 6,502 shares Expires 2031-06-15 F4 · derivative.exercise_price: Effective as of the Distribution, each outstanding option to purchase common shares of RemainCo was adjusted so that such option became an option to acquire Common Shares and an option to acquire RemainCo common shares. As a result, the Reporting Person acquired options to acquire the Issuer's Common Shares in an amount determined in accordance with the Separation Agreement. F4 · shares: Effective as of the Distribution, each outstanding option to purchase common shares of RemainCo was adjusted so that such option became an option to acquire Common Shares and an option to acquire RemainCo common shares. As a result, the Reporting Person acquired options to acquire the Issuer's Common Shares in an amount determined in accordance with the Separation Agreement. F4 · price: Effective as of the Distribution, each outstanding option to purchase common shares of RemainCo was adjusted so that such option became an option to acquire Common Shares and an option to acquire RemainCo common shares. As a result, the Reporting Person acquired options to acquire the Issuer's Common Shares in an amount determined in accordance with the Separation Agreement. F4 · derivative.exercise_date: Effective as of the Distribution, each outstanding option to purchase common shares of RemainCo was adjusted so that such option became an option to acquire Common Shares and an option to acquire RemainCo common shares. As a result, the Reporting Person acquired options to acquire the Issuer's Common Shares in an amount determined in accordance with the Separation Agreement. F4 · derivative.expiration_date: Effective as of the Distribution, each outstanding option to purchase common shares of RemainCo was adjusted so that such option became an option to acquire Common Shares and an option to acquire RemainCo common shares. As a result, the Reporting Person acquired options to acquire the Issuer's Common Shares in an amount determined in accordance with the Separation Agreement. Read SEC document |
| October 03, 2022 Filed Oct 5, 2022 21:39 UTC | Biohaven Ltd. BHVN · Entity 4379 | OtherStock Options (Right to Buy) · Derivative | 4,119 | Not disclosed Strike: $4.84 | Not disclosed |
DisclosureSEC source: 0001562180-22-007081 · primarydocument.xml · derivative · entry 8 Mehta Kishan · CIK 0001850520 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,119 Underlying: Common Shares · 4,119 shares Expires 2032-04-28 F4 · derivative.exercise_price: Effective as of the Distribution, each outstanding option to purchase common shares of RemainCo was adjusted so that such option became an option to acquire Common Shares and an option to acquire RemainCo common shares. As a result, the Reporting Person acquired options to acquire the Issuer's Common Shares in an amount determined in accordance with the Separation Agreement. F4 · shares: Effective as of the Distribution, each outstanding option to purchase common shares of RemainCo was adjusted so that such option became an option to acquire Common Shares and an option to acquire RemainCo common shares. As a result, the Reporting Person acquired options to acquire the Issuer's Common Shares in an amount determined in accordance with the Separation Agreement. F4 · price: Effective as of the Distribution, each outstanding option to purchase common shares of RemainCo was adjusted so that such option became an option to acquire Common Shares and an option to acquire RemainCo common shares. As a result, the Reporting Person acquired options to acquire the Issuer's Common Shares in an amount determined in accordance with the Separation Agreement. F4 · derivative.exercise_date: Effective as of the Distribution, each outstanding option to purchase common shares of RemainCo was adjusted so that such option became an option to acquire Common Shares and an option to acquire RemainCo common shares. As a result, the Reporting Person acquired options to acquire the Issuer's Common Shares in an amount determined in accordance with the Separation Agreement. F4 · derivative.expiration_date: Effective as of the Distribution, each outstanding option to purchase common shares of RemainCo was adjusted so that such option became an option to acquire Common Shares and an option to acquire RemainCo common shares. As a result, the Reporting Person acquired options to acquire the Issuer's Common Shares in an amount determined in accordance with the Separation Agreement. Read SEC document |
| October 03, 2022 Filed Oct 5, 2022 21:39 UTC | Biohaven Ltd. BHVN · Entity 4379 | Tax withholdingCommon Shares | 11,716 | $7.00 | $82,012.00 |
DisclosureSEC source: 0001562180-22-007081 · primarydocument.xml · nonDerivative · entry 7 Mehta Kishan · CIK 0001850520 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,662 F3 · shares: These shares were withheld by the Issuer in connection with share settlement to cover the cost of the stock options. Read SEC document |
| October 03, 2022 Filed Oct 5, 2022 21:39 UTC | Biohaven Ltd. BHVN · Entity 4379 | Exercise / conversionCommon Shares | 10,000 | $1.86 | $18,600.00 |
DisclosureSEC source: 0001562180-22-007081 · primarydocument.xml · nonDerivative · entry 6 Mehta Kishan · CIK 0001850520 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,378 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 03, 2022 Filed Oct 5, 2022 21:39 UTC | Biohaven Ltd. BHVN · Entity 4379 | Exercise / conversionCommon Shares | 7,500 | $2.58 | $19,350.00 |
DisclosureSEC source: 0001562180-22-007081 · primarydocument.xml · nonDerivative · entry 5 Mehta Kishan · CIK 0001850520 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,378 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 03, 2022 Filed Oct 5, 2022 21:39 UTC | Biohaven Ltd. BHVN · Entity 4379 | Exercise / conversionCommon Shares | 6,502 | $4.61 | $29,974.22 |
DisclosureSEC source: 0001562180-22-007081 · primarydocument.xml · nonDerivative · entry 4 Mehta Kishan · CIK 0001850520 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,878 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 03, 2022 Filed Oct 5, 2022 21:39 UTC | Biohaven Ltd. BHVN · Entity 4379 | Exercise / conversionCommon Shares | 4,119 | $4.84 | $19,935.96 |
DisclosureSEC source: 0001562180-22-007081 · primarydocument.xml · nonDerivative · entry 3 Mehta Kishan · CIK 0001850520 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,376 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 03, 2022 Filed Oct 5, 2022 21:39 UTC | Biohaven Ltd. BHVN · Entity 4379 | OtherCommon Shares | 937 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-22-007081 · primarydocument.xml · nonDerivative · entry 2 Mehta Kishan · CIK 0001850520 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,257 F2 · shares: Effective as of the Distribution, each outstanding restricted share unit of RemainCo was adjusted so that such restricted share unit became a restricted share unit in respect of Common Shares (each, an "Issuer RSU") and a restricted share unit in respect of RemainCo common shares. At the effective time of the merger of a wholly owned subsidiary of Pfizer ("Merger Sub") with and into RemainCo pursuant to the Agreement and Plan of Merger, dated as of May 9, 2022, by and among RemainCo, Pfizer and Merger Sub, the Issuer RSUs accelerated and vested in full and were subsequently settled in Common Shares. As a result, the Reporting Person acquired restricted share units in respect of Common Shares in an amount determined in accordance with the Separation Agreement. Read SEC document |
| October 03, 2022 Filed Oct 5, 2022 21:39 UTC | Biohaven Ltd. BHVN · Entity 4379 | OtherCommon Shares | 5,320 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-22-007081 · primarydocument.xml · nonDerivative · entry 1 Mehta Kishan · CIK 0001850520 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,320 F1 · shares: Represents common shares of the Issuer ("Common Shares") acquired by the Reporting Person in a pro rata distribution by Biohaven Pharmaceutical Holding Company Ltd.. ("RemainCo") to holders of its common shares (the "Distribution") pursuant to the Separation and Distribution Agreement (the "Separation Agreement"), dated as of May 9, 2022, by and among RemainCo, the Issuer, and Pfizer Inc. ("Pfizer"). Read SEC document |
| August 19, 2022 Filed Aug 23, 2022 17:28 UTC | Akili, Inc. AKLI · Entity 89130 | Exercise / conversionClass B ordinary shares · Derivative | 6,220,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-047241 · doc4.xml · derivative · entry 3 SCS Sponsor I LLC · CIK 0001850369 · Former Director and 10% Owner Mehta Kishan · CIK 0001850520 · Former Director and 10% Owner Cowen Aaron · CIK 0001869640 · Former Director and 10% Owner ChaChaCha DNA I, LLC · CIK 0001869714 · Former Director and 10% Owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Class A ordinary shares · 6,220,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: The Class B ordinary shares converted to Common Stock on a one-for-one basis upon the consummation of the Business Combination. F4 · derivative.exercise_date: The Class B ordinary shares converted to Common Stock on a one-for-one basis upon the consummation of the Business Combination. F4 · derivative.expiration_date: The Class B ordinary shares converted to Common Stock on a one-for-one basis upon the consummation of the Business Combination. F1 · ownership.direct: The Class B ordinary shares, par value $0.0001 per share (each a "Class B ordinary share"), held by the reporting owner, SCS Sponsor I LLC (the "Sponsor"), converted to the Issuer's common stock, par value $0.0001 per share ("Common Stock"), on a one-for-one basis upon the consummation of the business combination between the Issuer and Akili Interactive Labs, Inc. (the "Business Combination"). F2 · ownership.direct: The Sponsor is managed by its managers, Chamath Palihapitiya and Kishan Mehta. A majority of the voting interests of the Sponsor are held by SC SPAC Holdings LLC, the successor by merger to ChaChaCha DNA I, LLC ("SC SPAC Holdings"). Messrs. Mehta and Cowen may be deemed to control the other member of the Sponsor. Messrs. Mehta and Cowen and SC SPAC Holdings may be deemed to beneficially own shares held by the Sponsor by virtue of their direct or indirect interests in the Sponsor or their shared control over the Sponsor, as the case may be. Read SEC document |
| August 19, 2022 Filed Aug 23, 2022 17:28 UTC | Akili, Inc. AKLI · Entity 89130 | OtherCommon Stock | 6,860,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-047241 · doc4.xml · nonDerivative · entry 2 SCS Sponsor I LLC · CIK 0001850369 · Former Director and 10% Owner Mehta Kishan · CIK 0001850520 · Former Director and 10% Owner Cowen Aaron · CIK 0001869640 · Former Director and 10% Owner ChaChaCha DNA I, LLC · CIK 0001869714 · Former Director and 10% Owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F3 · ownership.direct: Represents the distribution for no consideration by the Sponsor of 6,860,000 shares of Common Stock to its members pro rata in accordance with their respective interests. Read SEC document |
| August 19, 2022 Filed Aug 23, 2022 17:28 UTC | Akili, Inc. AKLI · Entity 89130 | Exercise / conversionCommon Stock | 6,220,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-047241 · doc4.xml · nonDerivative · entry 1 SCS Sponsor I LLC · CIK 0001850369 · Former Director and 10% Owner Mehta Kishan · CIK 0001850520 · Former Director and 10% Owner Cowen Aaron · CIK 0001869640 · Former Director and 10% Owner ChaChaCha DNA I, LLC · CIK 0001869714 · Former Director and 10% Owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,860,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · ownership.direct: The Class B ordinary shares, par value $0.0001 per share (each a "Class B ordinary share"), held by the reporting owner, SCS Sponsor I LLC (the "Sponsor"), converted to the Issuer's common stock, par value $0.0001 per share ("Common Stock"), on a one-for-one basis upon the consummation of the business combination between the Issuer and Akili Interactive Labs, Inc. (the "Business Combination"). F2 · ownership.direct: The Sponsor is managed by its managers, Chamath Palihapitiya and Kishan Mehta. A majority of the voting interests of the Sponsor are held by SC SPAC Holdings LLC, the successor by merger to ChaChaCha DNA I, LLC ("SC SPAC Holdings"). Messrs. Mehta and Cowen may be deemed to control the other member of the Sponsor. Messrs. Mehta and Cowen and SC SPAC Holdings may be deemed to beneficially own shares held by the Sponsor by virtue of their direct or indirect interests in the Sponsor or their shared control over the Sponsor, as the case may be. Read SEC document |
| July 11, 2022 Filed Jul 13, 2022 16:25 UTC | PROKIDNEY CORP. PROK · Entity 5181 | Exercise / conversionClass B ordinary shares · Derivative | 6,220,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-042045 · doc4.xml · derivative · entry 3 SCS Sponsor III LLC · CIK 0001850379 · Former Director and 10% Owner Mehta Kishan · CIK 0001850520 · Former Director and 10% Owner Cowen Aaron · CIK 0001869640 · Former Director and 10% Owner ChaChaCha DNA III, LLC · CIK 0001869713 · Former Director and 10% Owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Class A ordinary shares · 6,220,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: The Class B ordinary shares were automatically convertible into Class A ordinary shares at the time of the issuer's initial business combination, or earlier at the option of the holder, on a one-for-one basis, subject to certain adjustments, and had no expiration date. F4 · derivative.exercise_date: The Class B ordinary shares were automatically convertible into Class A ordinary shares at the time of the issuer's initial business combination, or earlier at the option of the holder, on a one-for-one basis, subject to certain adjustments, and had no expiration date. F4 · derivative.expiration_date: The Class B ordinary shares were automatically convertible into Class A ordinary shares at the time of the issuer's initial business combination, or earlier at the option of the holder, on a one-for-one basis, subject to certain adjustments, and had no expiration date. F1 · ownership.direct: The Class B ordinary shares held by the reporting owner, SCS Sponsor III LLC (the "Sponsor"), converted to Class A ordinary shares on a one-for-one basis upon the consummation of the business combination between the issuer and ProKidney LP. F2 · ownership.direct: The Sponsor is managed by its managers, Chamath Palihapitiya and Kishan Mehta. A majority of the voting interests of the Sponsor are held by SC SPAC Holdings LLC, the successor by merger to ChaChaCha DNA III, LLC ("SC SPAC Holdings"). Messrs. Mehta and Cowen may be deemed to control the other member of the Sponsor. Messrs. Mehta and Cowen and SC SPAC Holdings may be deemed to beneficially own shares held by the Sponsor by virtue of their direct or indirect interests in the Sponsor or their shared control over the Sponsor, as the case may be. Read SEC document |
| July 11, 2022 Filed Jul 13, 2022 16:25 UTC | PROKIDNEY CORP. PROK · Entity 5181 | OtherClass A ordinary shares | 6,860,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-042045 · doc4.xml · nonDerivative · entry 2 SCS Sponsor III LLC · CIK 0001850379 · Former Director and 10% Owner Mehta Kishan · CIK 0001850520 · Former Director and 10% Owner Cowen Aaron · CIK 0001869640 · Former Director and 10% Owner ChaChaCha DNA III, LLC · CIK 0001869713 · Former Director and 10% Owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F3 · ownership.direct: Represents the distribution for no consideration by the Sponsor of 6,860,000 Class A ordinary shares to its members pro rata in accordance with their respective interests. Read SEC document |
| July 11, 2022 Filed Jul 13, 2022 16:25 UTC | PROKIDNEY CORP. PROK · Entity 5181 | Exercise / conversionClass A ordinary shares | 6,220,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-042045 · doc4.xml · nonDerivative · entry 1 SCS Sponsor III LLC · CIK 0001850379 · Former Director and 10% Owner Mehta Kishan · CIK 0001850520 · Former Director and 10% Owner Cowen Aaron · CIK 0001869640 · Former Director and 10% Owner ChaChaCha DNA III, LLC · CIK 0001869713 · Former Director and 10% Owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,860,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · ownership.direct: The Class B ordinary shares held by the reporting owner, SCS Sponsor III LLC (the "Sponsor"), converted to Class A ordinary shares on a one-for-one basis upon the consummation of the business combination between the issuer and ProKidney LP. F2 · ownership.direct: The Sponsor is managed by its managers, Chamath Palihapitiya and Kishan Mehta. A majority of the voting interests of the Sponsor are held by SC SPAC Holdings LLC, the successor by merger to ChaChaCha DNA III, LLC ("SC SPAC Holdings"). Messrs. Mehta and Cowen may be deemed to control the other member of the Sponsor. Messrs. Mehta and Cowen and SC SPAC Holdings may be deemed to beneficially own shares held by the Sponsor by virtue of their direct or indirect interests in the Sponsor or their shared control over the Sponsor, as the case may be. Read SEC document |
| April 28, 2022 Filed Apr 29, 2022 21:04 UTC | Biohaven Pharmaceutical Holding Co Ltd. BHVN · Entity 123269 | GrantStock Option (Right to Buy) · Derivative | 8,239 | $0.00 Strike: $97.74 | $0.00 |
DisclosureSEC source: 0001562180-22-003588 · primarydocument.xml · derivative · entry 1 Mehta Kishan · CIK 0001850520 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,239 Underlying: Common Shares · 8,239 shares Expires 2032-04-27 F1 · derivative.exercise_date: The shares subject to this stock option will vest in full on the earlier of (a) April 28, 2023 or (b) the date of the 2023 Annual Meeting of Shareholders, in each case subject to the Reporting Person's continuous service with the Issuer through such vesting date. Read SEC document |
| January 10, 2022 Filed Jan 12, 2022 21:04 UTC | Biohaven Pharmaceutical Holding Co Ltd. BHVN · Entity 123269 | Exercise / conversionRestricted Share Unit Award · Derivative | 1,875 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-22-000436 · primarydocument.xml · derivative · entry 2 Mehta Kishan · CIK 0001850520 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,875 Underlying: Common Shares · 1,875 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: Each restricted share unit represents the contingent right to receive one common share of the Issuer. F1 · derivative.exercise_price: Each restricted share unit represents the contingent right to receive one common share of the Issuer. F1 · price: Each restricted share unit represents the contingent right to receive one common share of the Issuer. F2 · derivative.exercise_date: The reporting person was granted 7,500 restricted share units on January 8, 2020, vesting in four equal installments on January 8, 2020, 2021, 2022 and 2023, subject to the reporting person's continued service with the Issuer at each vesting date. F3 · derivative.expiration_date: Not applicable. Read SEC document |
| January 10, 2022 Filed Jan 12, 2022 21:04 UTC | Biohaven Pharmaceutical Holding Co Ltd. BHVN · Entity 123269 | Exercise / conversionCommon Shares | 1,875 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-22-000436 · primarydocument.xml · nonDerivative · entry 1 Mehta Kishan · CIK 0001850520 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,640 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 16, 2021 Filed Aug 16, 2021 18:28 UTC | Social Capital Suvretta Holdings Corp. II DNAB · Entity 125597 | Disposition to issuerClass B ordinary shares · Derivative | 75,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-051677 · doc4.xml · derivative · entry 1 SCS Sponsor II LLC · CIK 0001850373 · Director · 10% owner Palihapitiya Chamath · CIK 0001715450 · Director · Chief Executive Officer · 10% owner Mehta Kishan · CIK 0001850520 · Director · President · 10% owner Cowen Aaron · CIK 0001869640 · 10% owner ChaChaCha DNA II, LLC · CIK 0001869716 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,220,000 Underlying: Class A ordinary shares · 75,000 shares Expires not disclosed F1 · derivative.exercise_price: As described in the issuer's registration statement on Form S-1 (File No. 333-256724) under the heading "Description of Securities--Founder Shares," the Class B ordinary shares, par value $0.0001 per share, of the issuer will automatically convert into Class A ordinary shares, par value $0.0001 per share, of the issuer at the time of the issuer's initial business combination, or earlier at the option of the holder, on a one-for-one basis, subject to certain adjustment, and have no expiration date. F2 · kind: On August 16, 2021, SCS Sponsor II LLC forfeited at no cost 75,000 shares of Class B ordinary shares of the issuer in connection with the election by the underwriters of the issuer's initial public offering to decline to exercise in full their option to purchase additional Class A ordinary shares. F1 · derivative.exercise_date: As described in the issuer's registration statement on Form S-1 (File No. 333-256724) under the heading "Description of Securities--Founder Shares," the Class B ordinary shares, par value $0.0001 per share, of the issuer will automatically convert into Class A ordinary shares, par value $0.0001 per share, of the issuer at the time of the issuer's initial business combination, or earlier at the option of the holder, on a one-for-one basis, subject to certain adjustment, and have no expiration date. F1 · derivative.expiration_date: As described in the issuer's registration statement on Form S-1 (File No. 333-256724) under the heading "Description of Securities--Founder Shares," the Class B ordinary shares, par value $0.0001 per share, of the issuer will automatically convert into Class A ordinary shares, par value $0.0001 per share, of the issuer at the time of the issuer's initial business combination, or earlier at the option of the holder, on a one-for-one basis, subject to certain adjustment, and have no expiration date. F3 · ownership.direct: The reporting owner, SCS Sponsor II LLC (the "Sponsor"), in whose name the securities reported herein are held, is managed by its managers, Chamath Palihapitiya and Kishan Mehta. A majority of the voting interests of the Sponsor are held by ChaChaCha DNA II, LLC ("ChaChaCha"), which is controlled by Mr. Palihapitiya. Messrs. Mehta and Cowen may be deemed to control the other member of the Sponsor. Messrs. Palihapitiya, Mehta and Cowen and ChaChaCha may be deemed to beneficially own shares held by the Sponsor by virtue of their direct or indirect interests in the Sponsor or their shared control over the Sponsor, as the case may be. Each of Mr. Palihapitiya, Mr. Mehta, ChaChaCha and Mr. Cowen disclaims beneficial ownership of the shares held by the Sponsor, except to the extent of such person's pecuniary interest therein. Read SEC document |
| August 16, 2021 Filed Aug 16, 2021 18:31 UTC | PROKIDNEY CORP. DNAC · Entity 5181 | Disposition to issuerClass B ordinary shares · Derivative | 75,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-051681 · doc4.xml · derivative · entry 1 SCS Sponsor III LLC · CIK 0001850379 · Director · 10% owner Palihapitiya Chamath · CIK 0001715450 · Director · Chief Executive Officer · 10% owner Mehta Kishan · CIK 0001850520 · Director · President · 10% owner Cowen Aaron · CIK 0001869640 · 10% owner ChaChaCha DNA III, LLC · CIK 0001869713 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,220,000 Underlying: Class A ordinary shares · 75,000 shares Expires not disclosed F1 · derivative.exercise_price: As described in the issuer's registration statement on Form S-1 (File No. 333-256725) under the heading "Description of Securities--Founder Shares," the Class B ordinary shares, par value $0.0001 per share, of the issuer will automatically convert into Class A ordinary shares, par value $0.0001 per share, of the issuer at the time of the issuer's initial business combination, or earlier at the option of the holder, on a one-for-one basis, subject to certain adjustment, and have no expiration date. F2 · kind: On August 16, 2021, SCS Sponsor III LLC forfeited at no cost 75,000 shares of Class B common stock of the issuer in connection with the election by the underwriters of the issuer's initial public offering to decline to exercise in full their option to purchase additional Class A ordinary shares. F1 · derivative.exercise_date: As described in the issuer's registration statement on Form S-1 (File No. 333-256725) under the heading "Description of Securities--Founder Shares," the Class B ordinary shares, par value $0.0001 per share, of the issuer will automatically convert into Class A ordinary shares, par value $0.0001 per share, of the issuer at the time of the issuer's initial business combination, or earlier at the option of the holder, on a one-for-one basis, subject to certain adjustment, and have no expiration date. F1 · derivative.expiration_date: As described in the issuer's registration statement on Form S-1 (File No. 333-256725) under the heading "Description of Securities--Founder Shares," the Class B ordinary shares, par value $0.0001 per share, of the issuer will automatically convert into Class A ordinary shares, par value $0.0001 per share, of the issuer at the time of the issuer's initial business combination, or earlier at the option of the holder, on a one-for-one basis, subject to certain adjustment, and have no expiration date. F3 · ownership.direct: The reporting owner, SCS Sponsor III LLC (the "Sponsor"), in whose name the securities reported herein are held, is managed by its managers, Chamath Palihapitiya and Kishan Mehta. A majority of the voting interests of the Sponsor are held by ChaChaCha DNA III, LLC ("ChaChaCha"), which is controlled by Mr. Palihapitiya. Messrs. Mehta and Cowen may be deemed to control the other member of the Sponsor. Messrs. Palihapitiya, Mehta and Cowen and ChaChaCha may be deemed to beneficially own shares held by the Sponsor by virtue of their direct or indirect interests in the Sponsor or their shared control over the Sponsor, as the case may be. Each of Mr. Palihapitiya, Mr. Mehta, ChaChaCha and Mr. Cowen disclaims beneficial ownership of the shares held by the Sponsor, except to the extent of such person's pecuniary interest therein. Read SEC document |
| August 16, 2021 Filed Aug 16, 2021 18:34 UTC | Social Capital Suvretta Holdings Corp. IV DNAD · Entity 123913 | Disposition to issuerClass B ordinary shares · Derivative | 75,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-051683 · doc4.xml · derivative · entry 1 SCS Sponsor IV LLC · CIK 0001850376 · Director · 10% owner Palihapitiya Chamath · CIK 0001715450 · Director · Chief Executive Officer · 10% owner Mehta Kishan · CIK 0001850520 · Director · President · 10% owner Cowen Aaron · CIK 0001869640 · 10% owner ChaChaCha DNA IV, LLC · CIK 0001869773 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,220,000 Underlying: Class A ordinary shares · 75,000 shares Expires not disclosed F1 · derivative.exercise_price: As described in the issuer's registration statement on Form S-1 (File No. 333-256727) under the heading "Description of Securities--Founder Shares," the Class B ordinary shares, par value $0.0001 per share, of the issuer will automatically convert into Class A ordinary shares, par value $0.0001 per share, of the issuer at the time of the issuer's initial business combination, or earlier at the option of the holder, on a one-for-one basis, subject to certain adjustment, and have no expiration date. F2 · kind: On August 16, 2021, SCS Sponsor IV LLC forfeited at no cost 75,000 shares of Class B common stock of the issuer in connection with the election by the underwriters of the issuer's initial public offering to decline to exercise in full their option to purchase additional Class A ordinary shares. F1 · derivative.exercise_date: As described in the issuer's registration statement on Form S-1 (File No. 333-256727) under the heading "Description of Securities--Founder Shares," the Class B ordinary shares, par value $0.0001 per share, of the issuer will automatically convert into Class A ordinary shares, par value $0.0001 per share, of the issuer at the time of the issuer's initial business combination, or earlier at the option of the holder, on a one-for-one basis, subject to certain adjustment, and have no expiration date. F1 · derivative.expiration_date: As described in the issuer's registration statement on Form S-1 (File No. 333-256727) under the heading "Description of Securities--Founder Shares," the Class B ordinary shares, par value $0.0001 per share, of the issuer will automatically convert into Class A ordinary shares, par value $0.0001 per share, of the issuer at the time of the issuer's initial business combination, or earlier at the option of the holder, on a one-for-one basis, subject to certain adjustment, and have no expiration date. F3 · ownership.direct: The reporting owner, SCS Sponsor IV LLC (the "Sponsor"), in whose name the securities reported herein are held, is managed by its managers, Chamath Palihapitiya and Kishan Mehta. A majority of the voting interests of the Sponsor are held by ChaChaCha DNA IV, LLC ("ChaChaCha"), which is controlled by Mr. Palihapitiya. Messrs. Mehta and Cowen may be deemed to control the other member of the Sponsor. Messrs. Palihapitiya, Mehta and Cowen and ChaChaCha may be deemed to beneficially own shares held by the Sponsor by virtue of their direct or indirect interests in the Sponsor or their shared control over the Sponsor, as the case may be. Each of Mr. Palihapitiya, Mr. Mehta, ChaChaCha and Mr. Cowen disclaims beneficial ownership of the shares held by the Sponsor, except to the extent of such person's pecuniary interest therein. Read SEC document |
| August 16, 2021 Filed Aug 16, 2021 18:25 UTC | Akili, Inc. DNAA · Entity 89130 | Disposition to issuerClass B ordinary shares · Derivative | 75,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-051674 · doc4.xml · derivative · entry 1 SCS Sponsor I LLC · CIK 0001850369 · Director · 10% owner Palihapitiya Chamath · CIK 0001715450 · Director · Chief Executive Officer · 10% owner Mehta Kishan · CIK 0001850520 · Director · President · 10% owner Cowen Aaron · CIK 0001869640 · 10% owner ChaChaCha DNA I, LLC · CIK 0001869714 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,220,000 Underlying: Class A ordinary shares · 75,000 shares Expires not disclosed F1 · derivative.exercise_price: As described in the issuer's registration statement on Form S-1 (File No. 333-256723) under the heading "Description of Securities--Founder Shares," the Class B ordinary shares, par value $0.0001 per share, of the issuer will automatically convert into Class A ordinary shares, par value $0.0001 per share, of the issuer at the time of the issuer's initial business combination, or earlier at the option of the holder, on a one-for-one basis, subject to certain adjustment, and have no expiration date. F2 · kind: On August 16, 2021, SCS Sponsor I LLC forfeited at no cost 75,000 shares of Class B ordinary shares of the issuer in connection with the election by the underwriters of the issuer's initial public offering to decline to exercise in full their option to purchase additional Class A ordinary shares. F1 · derivative.exercise_date: As described in the issuer's registration statement on Form S-1 (File No. 333-256723) under the heading "Description of Securities--Founder Shares," the Class B ordinary shares, par value $0.0001 per share, of the issuer will automatically convert into Class A ordinary shares, par value $0.0001 per share, of the issuer at the time of the issuer's initial business combination, or earlier at the option of the holder, on a one-for-one basis, subject to certain adjustment, and have no expiration date. F1 · derivative.expiration_date: As described in the issuer's registration statement on Form S-1 (File No. 333-256723) under the heading "Description of Securities--Founder Shares," the Class B ordinary shares, par value $0.0001 per share, of the issuer will automatically convert into Class A ordinary shares, par value $0.0001 per share, of the issuer at the time of the issuer's initial business combination, or earlier at the option of the holder, on a one-for-one basis, subject to certain adjustment, and have no expiration date. F3 · ownership.direct: The reporting owner, SCS Sponsor I LLC (the "Sponsor"), in whose name the securities reported herein are held, is managed by its managers, Chamath Palihapitiya and Kishan Mehta. A majority of the voting interests of the Sponsor are held by ChaChaCha DNA I, LLC ("ChaChaCha"), which is controlled by Mr. Palihapitiya. Messrs. Mehta and Cowen may be deemed to control the other member of the Sponsor. Messrs. Palihapitiya, Mehta and Cowen and ChaChaCha may be deemed to beneficially own shares held by the Sponsor by virtue of their direct or indirect interests in the Sponsor or their shared control over the Sponsor, as the case may be. Each of Mr. Palihapitiya, Mr. Mehta, ChaChaCha and Mr. Cowen disclaims beneficial ownership of the shares held by the Sponsor, except to the extent of such person's pecuniary interest therein. Read SEC document |
| July 02, 2021 Filed Jul 7, 2021 20:47 UTC | Social Capital Suvretta Holdings Corp. II DNAB · Entity 125597 | GrantClass A ordinary shares | 640,000 | $10.00 | $6,400,000.00 |
DisclosureSEC source: 0001209191-21-045951 · doc4.xml · nonDerivative · entry 1 SCS Sponsor II LLC · CIK 0001850373 · Director · 10% owner Palihapitiya Chamath · CIK 0001715450 · Director · Chief Executive Officer · 10% owner Mehta Kishan · CIK 0001850520 · Director · President · 10% owner Cowen Aaron · CIK 0001869640 · 10% owner ChaChaCha DNA II, LLC · CIK 0001869716 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 640,000 F1 · ownership.direct: The reporting owner, SCS Sponsor II LLC (the "Sponsor"), in whose name the securities reported herein are held, is managed by its managers, Chamath Palihapitiya and Kishan Mehta. A majority of the voting interests of the Sponsor are held by ChaChaCha DNA II, LLC ("ChaChaCha"), which is controlled by Mr. Palihapitiya. Messrs. Mehta and Cowen may be deemed to control the other member of the Sponsor. Messrs. Palihapitiya, Mehta and Cowen and ChaChaCha may be deemed to beneficially own shares held by the Sponsor by virtue of their direct or indirect interests in the Sponsor or their shared control over the Sponsor, as the case may be. Each of Mr. Palihapitiya, Mr. Mehta, ChaChaCha and Mr. Cowen disclaims beneficial ownership of the shares held by the Sponsor, except to the extent of such person's pecuniary interest therein. Read SEC document |
| July 02, 2021 Filed Jul 7, 2021 20:52 UTC | PROKIDNEY CORP. DNAC · Entity 5181 | GrantClass A ordinary shares | 640,000 | $10.00 | $6,400,000.00 |
DisclosureSEC source: 0001209191-21-045953 · doc4.xml · nonDerivative · entry 1 SCS Sponsor III LLC · CIK 0001850379 · Director · 10% owner Palihapitiya Chamath · CIK 0001715450 · Director · Chief Executive Officer · 10% owner Mehta Kishan · CIK 0001850520 · Director · President · 10% owner Cowen Aaron · CIK 0001869640 · 10% owner ChaChaCha DNA III, LLC · CIK 0001869713 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 640,000 F1 · ownership.direct: The reporting owner, SCS Sponsor III LLC (the "Sponsor"), in whose name the securities reported herein are held, is managed by its managers, Chamath Palihapitiya and Kishan Mehta. A majority of the voting interests of the Sponsor are held by ChaChaCha DNA III, LLC ("ChaChaCha"), which is controlled by Mr. Palihapitiya. Messrs. Mehta and Cowen may be deemed to control the other member of the Sponsor. Messrs. Palihapitiya, Mehta and Cowen and ChaChaCha may be deemed to beneficially own shares held by the Sponsor by virtue of their direct or indirect interests in the Sponsor or their shared control over the Sponsor, as the case may be. Each of Mr. Palihapitiya, Mr. Mehta, ChaChaCha and Mr. Cowen disclaims beneficial ownership of the shares held by the Sponsor, except to the extent of such person's pecuniary interest therein. Read SEC document |
| July 02, 2021 Filed Jul 7, 2021 20:42 UTC | Akili, Inc. DNAA · Entity 89130 | GrantClass A ordinary shares | 640,000 | $10.00 | $6,400,000.00 |
DisclosureSEC source: 0001209191-21-045949 · doc4.xml · nonDerivative · entry 1 SCS Sponsor I LLC · CIK 0001850369 · Director · 10% owner Palihapitiya Chamath · CIK 0001715450 · Director · Chief Executive Officer · 10% owner Mehta Kishan · CIK 0001850520 · Director · President · 10% owner Cowen Aaron · CIK 0001869640 · 10% owner ChaChaCha DNA I, LLC · CIK 0001869714 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 640,000 F1 · ownership.direct: The reporting owner, SCS Sponsor I LLC (the "Sponsor"), in whose name the securities reported herein are held, is managed by its managers, Chamath Palihapitiya and Kishan Mehta. A majority of the voting interests of the Sponsor are held by ChaChaCha DNA I, LLC ("ChaChaCha"), which is controlled by Mr. Palihapitiya. Messrs. Mehta and Cowen may be deemed to control the other member of the Sponsor. Messrs. Palihapitiya, Mehta and Cowen and ChaChaCha may be deemed to beneficially own shares held by the Sponsor by virtue of their direct or indirect interests in the Sponsor or their shared control over the Sponsor, as the case may be. Each of Mr. Palihapitiya, Mr. Mehta, ChaChaCha and Mr. Cowen disclaims beneficial ownership of the shares held by the Sponsor, except to the extent of such person's pecuniary interest therein. Read SEC document |
| July 02, 2021 Filed Jul 7, 2021 20:56 UTC | Social Capital Suvretta Holdings Corp. IV DNAD · Entity 123913 | GrantClass A ordinary shares | 640,000 | $10.00 | $6,400,000.00 |
DisclosureSEC source: 0001209191-21-045954 · doc4.xml · nonDerivative · entry 1 SCS Sponsor IV LLC · CIK 0001850376 · Director · 10% owner Palihapitiya Chamath · CIK 0001715450 · Director · Chief Executive Officer · 10% owner Mehta Kishan · CIK 0001850520 · Director · President · 10% owner Cowen Aaron · CIK 0001869640 · 10% owner ChaChaCha DNA IV, LLC · CIK 0001869773 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 640,000 F1 · ownership.direct: The reporting owner, SCS Sponsor IV LLC (the "Sponsor"), in whose name the securities reported herein are held, is managed by its managers, Chamath Palihapitiya and Kishan Mehta. A majority of the voting interests of the Sponsor are held by ChaChaCha DNA IV, LLC ("ChaChaCha"), which is controlled by Mr. Palihapitiya. Messrs. Mehta and Cowen may be deemed to control the other member of the Sponsor. Messrs. Palihapitiya, Mehta and Cowen and ChaChaCha may be deemed to beneficially own shares held by the Sponsor by virtue of their direct or indirect interests in the Sponsor or their shared control over the Sponsor, as the case may be. Each of Mr. Palihapitiya, Mr. Mehta, ChaChaCha and Mr. Cowen disclaims beneficial ownership of the shares held by the Sponsor, except to the extent of such person's pecuniary interest therein. Read SEC document |
| June 15, 2021 Filed Jun 17, 2021 21:51 UTC | Biohaven Pharmaceutical Holding Co Ltd. BHVN · Entity 123269 | GrantStock Options (Right to buy) · Derivative | 13,004 | $0.00 Strike: $93.21 | $0.00 |
DisclosureSEC source: 0001562180-21-004379 · primarydocument.xml · derivative · entry 1 Mehta Kishan · CIK 0001850520 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,004 Underlying: Common Shares · 13,004 shares Expires 2031-06-15 F1 · derivative.exercise_date: This option grant was made pursuant to the issuer's non-employee director compensation policy. The common shares underlying this option vest in three equal installments on June 15, 2022, 2023, and 2024, subject to the reporting person's continuous service with the issuer at each vesting date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.